KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,189,881 | +7.4% | 100,059 | +35.4% | 0.00% | 0.0% |
| Q2 2023 | $2,969,583 | +11.7% | 73,907 | +18.7% | 0.00% | 0.0% |
| Q1 2023 | $2,658,502 | -62.0% | 62,260 | -57.3% | 0.00% | -50.0% |
| Q4 2022 | $7,002,373 | +5.5% | 145,822 | -17.3% | 0.00% | 0.0% |
| Q3 2022 | $6,635,000 | +62.4% | 176,364 | +19.3% | 0.00% | +100.0% |
| Q2 2022 | $4,086,000 | -41.2% | 147,851 | +15.7% | 0.00% | 0.0% |
| Q1 2022 | $6,952,000 | -0.4% | 127,831 | +7.2% | 0.00% | 0.0% |
| Q4 2021 | $6,980,000 | +239.8% | 119,298 | +129.8% | 0.00% | – |
| Q3 2021 | $2,054,000 | +115.3% | 51,909 | +131.0% | 0.00% | – |
| Q2 2021 | $954,000 | +143.4% | 22,470 | +253.2% | 0.00% | – |
| Q1 2021 | $392,000 | -95.5% | 6,362 | -94.9% | 0.00% | -100.0% |
| Q4 2020 | $8,741,000 | +1179.8% | 123,915 | +599.4% | 0.00% | – |
| Q3 2020 | $683,000 | – | 17,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |